Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rona Yaeger

Showing results (11-20 of 176) with videos related to

Pageof 18
Sort By:
Developmental Cell|September 12, 2023
KRAS<sup>G12D</sup> inhibition in pancreatic cancer: Fas expression facilitates immune clearanceCeline Yeh, Wungki Park, Rona Yaeger
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|June 1, 2017
Systemic Therapy for Metastatic Colorectal Cancer: From Current Standards to Future Molecular Targeted ApproachesChloe E Atreya, Rona Yaeger, Edward Chu
JCO Precision Oncology|February 9, 2022
Intermittent Treatment With MEK Inhibitors in Patients With Oncogenic RAF-Driven Tumors: A Potential Strategy to Manage Toxicity and Maintain EfficacyRona Yaeger, Zhan Yao, Paul B Chapman
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 29, 2022
Molecular Pathways and Mechanisms of BRAF in Cancer TherapyPoulikos I Poulikakos, Ryan J Sullivan, Rona Yaeger
JCO Precision Oncology|March 26, 2019
Balancing RAF, MEK, and EGFR inhibitor doses to achieve clinical responses and modulate toxicity in <i>BRAF</i> V600E colorectal cancerSebastian Mondaca, Mario Lacouture, Jonathan Hersch, et al.
JAMA Oncology|July 17, 2015
Axillary Lymph Node Involvement, a Unique Pattern of Metastasis in BRAF-Mutant Colorectal CancerMarla D Lipsyc, Rona Yaeger, Lynn T Dengel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 2022
<i>BRAF</i>-Mutated Advanced Colorectal Cancer: A Rapidly Changing Therapeutic LandscapeKristen K Ciombor, John H Strickler, Tanios S Bekaii-Saab, et al.
Nature Reviews. Clinical Oncology|June 6, 2025
Surrogate end points in oncology: aligning drug development incentives and patient needsMatthew Vogel, Rona Yaeger, David J Stewart, et al.
Gastroenterology|July 31, 2020
Specific Mutations in APC, but Not Alterations in DNA Damage Response, Associate With Outcomes of Patients With Metastatic Colorectal CancerSebastian Mondaca, Henry Walch, Subhiksha Nandakumar, et al.
Applied Immunohistochemistry & Molecular Morphology : AIMM|December 18, 2014
Immunohistochemical detection of the BRAF V600E mutant protein in colorectal neoplasmsEfsevia Vakiani, Rona Yaeger, Sylvester Brooke, et al.
Pageof 18

Showing results (11-20 of 176) with videos related to

Sort By:
Pageof 18
Developmental Cell|September 12, 2023
KRAS<sup>G12D</sup> inhibition in pancreatic cancer: Fas expression facilitates immune clearanceCeline Yeh, Wungki Park, Rona Yaeger
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|June 1, 2017
Systemic Therapy for Metastatic Colorectal Cancer: From Current Standards to Future Molecular Targeted ApproachesChloe E Atreya, Rona Yaeger, Edward Chu
JCO Precision Oncology|February 9, 2022
Intermittent Treatment With MEK Inhibitors in Patients With Oncogenic RAF-Driven Tumors: A Potential Strategy to Manage Toxicity and Maintain EfficacyRona Yaeger, Zhan Yao, Paul B Chapman
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 29, 2022
Molecular Pathways and Mechanisms of BRAF in Cancer TherapyPoulikos I Poulikakos, Ryan J Sullivan, Rona Yaeger
JCO Precision Oncology|March 26, 2019
Balancing RAF, MEK, and EGFR inhibitor doses to achieve clinical responses and modulate toxicity in <i>BRAF</i> V600E colorectal cancerSebastian Mondaca, Mario Lacouture, Jonathan Hersch, et al.
JAMA Oncology|July 17, 2015
Axillary Lymph Node Involvement, a Unique Pattern of Metastasis in BRAF-Mutant Colorectal CancerMarla D Lipsyc, Rona Yaeger, Lynn T Dengel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 2022
<i>BRAF</i>-Mutated Advanced Colorectal Cancer: A Rapidly Changing Therapeutic LandscapeKristen K Ciombor, John H Strickler, Tanios S Bekaii-Saab, et al.
Nature Reviews. Clinical Oncology|June 6, 2025
Surrogate end points in oncology: aligning drug development incentives and patient needsMatthew Vogel, Rona Yaeger, David J Stewart, et al.
Gastroenterology|July 31, 2020
Specific Mutations in APC, but Not Alterations in DNA Damage Response, Associate With Outcomes of Patients With Metastatic Colorectal CancerSebastian Mondaca, Henry Walch, Subhiksha Nandakumar, et al.
Applied Immunohistochemistry & Molecular Morphology : AIMM|December 18, 2014
Immunohistochemical detection of the BRAF V600E mutant protein in colorectal neoplasmsEfsevia Vakiani, Rona Yaeger, Sylvester Brooke, et al.
Pageof 18